Director, EHSS Performance & Systems Innovation at Bristol-Myers Squibb

Lawrence Township, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Bachelor’s degree in engineering, life sciences, information systems, or a related field; advanced degrees preferred
10+ years of progressive experience in EHSS, systems strategy, or related disciplines within a regulated industry
Proven leadership in developing and executing digital strategies across complex, global organizations
Experience with AI integration, data governance, and digital transformation initiatives
Experience and knowledge on application of data science concepts and statistical methods to power predictive analytics and insights
Strong stakeholder engagement and change management skills, with the ability to influence senior leaders
Professional EHS related certifications (e.g. CIH, CSP etc.)

Responsibilities

Lead EHSS performance enablement across the business, including development of forward-looking metrics, innovative application of data science, improvement of data quality, and delivery of standardized, actionable reporting
Partner with BI&T to apply data science methodologies, drive predictive analytics and develop visualization strategies in support of proactive risk management and performance improvement
Define and lead a unified EHSS systems strategy, ensuring alignment with enterprise objectives, risk priorities, and compliance requirements across all platforms
Establish governance frameworks for EHSS systems, including strategic prioritization, lifecycle planning, and performance monitoring
Champion innovation and emerging technologies (e.g., automation, AI-enabled tools) to optimize EHSS systems processes and enhance efficiency across the function
Partner with BI&T and other functions to deliver and sustain EHSS systems, enabling robust performance monitoring and reporting
Lead the multiyear roadmap for EHSS systems and applications, ensuring strategic integration and continuous improvement
Promote a culture of innovation and change readiness across the EHSS function

Skills

EHSS

Performance Metrics

Analytics

Data Quality

Predictive Insights

Systems Strategy

BI&T

Automation

Digital Processes

Risk Management

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free